NXTC Stock Analysis: Buy, Sell, or Hold?
NXTC - NextCure, Inc. Common Stock
$3.15
-0.25 (-7.35%)
▼
5d:
-48.11%
30d:
-64.69%
90d:
-75.0%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When NXTC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NXTC is down 48.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NXTC is down 48.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NXTC is currently trading at $3.15, which is considered oversold relative to its 30-day fair value range of $6.21 to $10.55.
Technical Outlook: Technically, NXTC is in a downtrend. Immediate support is located at $2.83, while resistance sits at $10.71. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.33 (+513.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NXTC is in a downtrend. Immediate support is located at $2.83, while resistance sits at $10.71. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.33 (+513.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.21 -
$10.55
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.4%)
- BULLISH: Trading 513.8% below Wall St target ($19.33)
- WARNING: Recommendation downgraded due to -48.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$6.21 -
$10.55
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.83
Resistance Level
$10.71
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.38
Wall Street Target
$19.33
(+513.8%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 04, 2026 4:11 AM ET
Data refreshes hourly during market hours. Next update: 5:11 AM
Data refreshes hourly during market hours. Next update: 5:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NXTC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 52 HOLD |
